⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
businesswire.com
IONS
Form 8-K
sec.gov
IONS
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
businesswire.com
IONS
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
KODK
RKDA
OTLK
UTHR
CLSD
AZN
BTE
CCNE
IONS
APLS
GYRO
NVS
GNTX
BLTE
JNJ
LCTX
ABBV
REGN
Next Generation Drug Conjugates Market Expected to Reach USD 42.55 Billion by 2035 | MarketsandMarkets™
globenewswire.com
AZN
NVS
ALNY
GILD
ABBV
IONS
SNY
Form 8-K
sec.gov
IONS
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
Form 8-K
sec.gov
IONS
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
businesswire.com
IONS